Vanda Pharmaceuticals Inc. (VNDA) has a significant regulatory catalyst to watch tomorrow.
The company's atypical antipsychotic Fanapt, proposed for the expanded use in treating bipolar I disorder, awaits the FDA decision on April 2, 2024.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com